Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Thatthan Suksombooncharoen et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver DiseaseВ. Т. Ивашкин, Минара Шамхаловна Шамхалова, М. V. Maevskaya et al.|Russian Journal of Gastroenterology Hepatology Coloproctology|2022Cited by 71
The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbiditiesМ. V. Maevskaya, Минара Шамхаловна Шамхалова, Yu. V. Kotovskaya et al.|Terapevticheskii arkhiv|2022Cited by 59